Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.39 |
| ▸ | RBP4 | P02753 | 4/20 | 0.38 |
| ▸ | CES2 | O00748 | 3/20 | 0.38 |
| ▸ | RXRA | P19793 | 1/20 | 0.36 |
| ▸ | RXRB | P28702 | 1/20 | 0.36 |
| ▸ | RXRG | P48443 | 1/20 | 0.36 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.35 |
| ▸ | LIPC | P11150 | 1/20 | 0.34 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6908816 | 0.86 | IDO1 (0.38) | MRGPRX4PTGDR2RBP4CES2 | |
| SCHEMBL16398462 | 0.84 | MRGPRX4 (0.41) | MRGPRX4PTGDR2KDM4CCES2RXRA | |
| SCHEMBL3369693 | 0.80 | CES2 (0.48) | CES2RXRARXRBRXRGGPR17 | |
| SCHEMBL422861 | 0.79 | MRGPRX4 (0.43) | MRGPRX4PTGDR2 | |
| SCHEMBL423246 | 0.74 | CES2 (0.43) | CES2RXRARXRBRXRGGPR17 | |
| SCHEMBL420887 | 0.74 | RXRA (0.46) | CES2RXRARXRBRXRGGPR17 | |
| SCHEMBL30532294 | 0.74 | CES2 (0.43) | CES2RXRARXRBRXRGGPR17 | |
| SCHEMBL22043721 | 0.74 | CES2 (0.43) | CES2RXRARXRBRXRGGPR17 | |
| SCHEMBL8037311 | 0.74 | CES2 (0.47) | CES2RXRARXRBRXRGGPR17 | |
| SCHEMBL16398013 | 0.73 | PTGDR2 (0.36) | MRGPRX4PTGDR2CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2470498-B1 | CARBOCYCLIC GLYT1 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2015-02-11 | — | — | EP | disclosed |
| EP-2470498-B1 | CARBOCYCLIC GLYT1 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2015-02-11 | — | — | EP | disclosed |
| CN-102740848-B | Tetrahydro-pyran derivatives against neurological illnesses | HOFFMANN LA ROCHE | 2014-08-27 | — | — | CN | disclosed |
| EP-2531190-B1 | TETRAHYDRO-PYRAN DERIVATIVES AGAINST NEUROLOGICAL ILLNESSES | HOFFMANN LA ROCHE (CH) | 2014-07-23 | — | — | EP | disclosed |
| EP-2531190-B1 | TETRAHYDRO-PYRAN DERIVATIVES AGAINST NEUROLOGICAL ILLNESSES | HOFFMANN LA ROCHE (CH) | 2014-07-23 | — | — | EP | disclosed |
| US-8524909-B2 | Tetrahydro-pyran derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-8524909-B2 | Tetrahydro-pyran derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-8524909-B2 | Tetrahydro-pyran derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-8404673-B2 | Carbocyclic GlyT1 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-8404673-B2 | Carbocyclic GlyT1 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2013-03-26 | — | — | US | disclosed |
| WO-2011095434-A1 | TETRAHYDRO-PYRAN DERIVATIVES AGAINST NEUROLOGICAL ILLNESSES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-08-11 | — | — | WO | disclosed |
| WO-2011095434-A1 | TETRAHYDRO-PYRAN DERIVATIVES AGAINST NEUROLOGICAL ILLNESSES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-08-11 | — | — | WO | disclosed |
| US-20110190349-A1 | TETRAHYDRO-PYRAN DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-08-04 | — | — | US | disclosed |
| US-20110190349-A1 | TETRAHYDRO-PYRAN DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-08-04 | — | — | US | disclosed |
| US-20110190349-A1 | TETRAHYDRO-PYRAN DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-08-04 | — | — | US | disclosed |
| US-20110053904-A1 | CARBOCYCLIC GLYT1 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-03 | — | — | US | disclosed |
| US-20110053904-A1 | CARBOCYCLIC GLYT1 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-03 | — | — | US | disclosed |
| US-20110053904-A1 | CARBOCYCLIC GLYT1 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-03 | — | — | US | disclosed |
| WO-2011023667-A1 | CARBOCYCLIC GLYT1 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-03 | — | — | WO | disclosed |
| WO-2011023667-A1 | CARBOCYCLIC GLYT1 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053904-A1 | CARBOCYCLIC GLYT1 RECEPTOR ANTAGONISTS | GRIA1, GLRA1, GRIA3 | MRGPRX4 162/4885PTGDR2 479/4885KDM4C 4012/4885 |
| US-20110190349-A1 | TETRAHYDRO-PYRAN DERIVATIVES | GLRA1, GRIA1, GLRA2 | MRGPRX4 1623/4885PTGDR2 357/4885KDM4C 3975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.